MP21-09 Drug-related sexual dysfunction issues among patients under treatment or previously exposed to selective serotonin reuptake inhibitors (SSRIs)—A management challenge?
Journal of Urology CME 1 May 2022. https://doi.org/10.1097/JU.0000000000002554.09 MP21-09 DRUG-RELATED SEXUAL DYSFUNCTION ISSUES AMONG PATIENTS UNDER TREATMENT OR PREVIOUSLY EXPOSED TO SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)—A MANAGEMENT CHALLENGE? Nicolo Schifano*, Milan, Italy; Paolo Capogrosso, Varese, Italy; Giuseppe Fallara, Edoardo Pozzi, Federico Belladelli, Luigi Candela, Christian Corsini, Massimiliano Raffo, Antonio Costa, Daniele Cignoli, Alessia d'Arma, Luca Boeri, Eugenio Ventimiglia, Rayan Matloob, Milan, Italy; Vincenzo Mirone, Naples, Italy; Federico Deho, Varese, Italy; Francesco Montorsi, Andrea Salonia, Milan, Italy Abstract INTRODUCTION AND OBJECTIVE: Sexual dysfunction (SD) issues, including erectile dysfunction (ED), low sexual desire (LSD), ejaculatory dysfunction, are common side effects of SSRIs. Some patients may continue to experience sexual side effects even after discontinuation of the antidepressant (Post-SSRI sexual dysfunction). The eviden